Response of TT virus to IFN plus ribavirin treatment in patients with chronic hepatitis C

Table 1 Features of patients in the study

PatientNo.	HCVGenotype	Fibrosis	Before treatment			End of treatment			6 months after treatment
			ALT	TTV	HCV	ALT	TTV	HCV	ALT	TTV	HCV
1	1a	I	51	1.7 × 105	5 × 105	26	-	-	83	+	ND
2	1a	III	139	1.5 × 103	9.4 × 105	35	-	-	19	ND	-
3	1a	III	102	1.7 × 103	8 × 105	30	-	-	11	+	-
4	1b	III	225	1.1 × 104	1.1 × 106	29	4 × 104	-	27	+	-
5	1a	II	82	1.4 × 103	9 × 105	30	-	-	168	+	1.9 × 106
6	1b	III	92	1.3 × 103	1.5 × 106	42	-	-	48	+	-
7	3a	II	117	1.8 × 104	2.4 × 106	9	-	-	23	ND	-
8	1b	III	102	-	1.5 × 106	59	-	-	39	-	-
9	1b	I	86	5.7 × 104	7 × 105	30	1.3 × 104	6 × 105	44	+	9.9 × 105
10	1b	I	183	-	9 × 104	26	-	-	17	+	-
11	1a	I	77	-	2.5 × 106	16	-	-	27	ND	-
12	1b	I	72	4.6 × 104	2 × 105	36	103	3.5 × 105	76	+	5 × 105
13	1a	III	101	-	2.3 × 105	47	-	3 × 104	153	ND	+
14	1b	I	68	-	5 × 105	29	-	-	56	-	2 × 105
15	1a	I	29	3.1 × 104	6.3 × 106	13	2.5 × 103	2.1 × 106	30	+	+

ALT level was expressed as IU/L. TTV and HCV loads were expressed as viral genomes/mL of serum.

Table 2 Changes of ALT levels in TTV and HCV responder and non-responder patients to PEG-IFN plus ribavirin therapy

	TTV		Pa	HCV		Pa
	Responders (n = 6)	Non-responders (n = 4)		Responders (n = 11)	Non-responders (n = 4)
Before therapy	97.16 ± 30.18	103.0 ± 84.87	0.09	112.54 ± 51.90	72.00 ± 31.01	0.33
End of therapy	28.66 ± 11.09	27.00 ± 9.83	0.92	30.09 ± 12.96	31.50 ± 14.20	0.76

ALT level was expressed as IU/L. ^aStudent´s t-test.